Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma

Br J Haematol. 2022 Mar;196(5):1274-1277. doi: 10.1111/bjh.17945. Epub 2021 Nov 8.

Authors

Rahul Banerjee¹, Shonali Midha², Amar H Kelkar³, Aaron Goodman⁴, Vinay Prasad¹, Ghulam Rehman Mohyuddin⁵

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
² Division of Myeloma, Department of Medical Oncology, Dana-Farber Cancer Institute, USA.
³ Division of Transplantation and Cellular Therapies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ University of California San Diego, San Diego, CA, USA.
⁵ University of Utah, Salt Lake City, UT, USA.

PMID: 34750805
DOI: 10.1111/bjh.17945

No abstract available

Keywords: clinical studies; malignant lymphomas; myeloma therapy.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use*
Antineoplastic Agents, Alkylating / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Biological Products / therapeutic use
Clinical Trials as Topic
Drug Discovery
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Melphalan / analogs & derivatives
Melphalan / therapeutic use
Multiple Myeloma / drug therapy*
Phenylalanine / analogs & derivatives
Phenylalanine / therapeutic use
Receptors, Antigen, T-Cell / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Immunological
Biological Products
Receptors, Antigen, T-Cell
melflufen
Phenylalanine
belantamab mafodotin
Melphalan
tisagenlecleucel
axicabtagene ciloleucel